Outset Medical (OM) announced the appointment of healthcare industry veteran Kevin O’Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O’Boyle’s appointment, the company also announced that Dale E. Jones has stepped down from the Board. O’Boyle served on the board of directors of Nevro Corp. from March 2019 through April 2025 when the company was acquired by Globus Medical, Inc. He also served as Chairman of the GenMark Diagnostics board until its acquisition by Roche in May 2021
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OM:
- Outset Medical’s Positive Earnings Call Highlights Growth
- Outset Medical price target raised to $14 from $12 at RBC Capital
- Outset Medical Reports Strong Q1 Growth and Improved Margins
- Outset Medical’s Strong Financial Performance and Growth Potential Justify Buy Rating
- Outset Medical reports Q1 EPS ($3.24)